周智锋 (Zhifeng Zhou)

Civil Aviation Flight University of China

H指数:21

被引数:1,812

个人简介

任职于福建医科大学基础医学院、福建省肿瘤医院免疫学研究室，肿瘤学硕士，福建医科大学、福州大学硕士生导师。主要从事肿瘤免疫的基础与临床转化及医工合作。

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

2018年福建省抗癌协会科技三等奖（2018）｜福建省抗癌协会

Air transportation carbon dioxide emission forecasting: An improved back propagation neural network

张, P.; 罗Y.; 俞Q.; 周Z. 航空运输二氧化碳排放预测: 一种改进的误差反向传播神经网络. PLoS ONE 2025, 20, e0333226. [Google Scholar] [CrossRef]

PLOS ONE

IF2.6

2025-10-071

PRE

Solasonine Restores Sensitivity of Gastric Cancer to NK Cells through DNA Demethylation of MICA

Solasonine通过MICA的DNA去甲基化恢复胃癌对NK细胞的敏感性

Advanced Biology

IF2.6

2025-08-070

PRE

Dap10 co-stimulation enhances the anti-HCC efficacy of NKp30 chimeric antigen receptor T cells

Dap10协同刺激增强了NKp30嵌合抗原受体T细胞的抗HCC效果

TRANSLATIONAL ONCOLOGY

IF4.1

2025-07-010

PRE

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

HER2阴性晚期胃或胃食管结合部腺癌中，一线卡度尼利单抗联合化疗的成本效益分析

FRONTIERS IN IMMUNOLOGY

IF5.9

2025-05-130

EIF3B affects the invasion and metastasis of hepatocellular carcinoma cells via the TGFBI/MAPK/ERK pathway

ANNALS OF HEPATOLOGY

IF4.4

2025-01-010

OAAI

Hsp90α promotes lipogenesis by stabilizing FASN and promoting FASN transcription via LXRα in hepatocellular carcinoma

JOURNAL OF LIPID RESEARCH

IF4.1

2025-01-010

PRE

Exosomal transfer of HCC-derived miR-17-5p downregulates NK cell function by targeting RUNX1-NKG2D axis

肝癌源性miR-17-5p的外泌体转移通过靶向RUNX1-NKG2D轴下调NK细胞功能

INTERNATIONAL IMMUNOPHARMACOLOGY

IF4.7

2024-07-013

PRE

RETRACTION: Long non-coding RNA KCNQ1OT1 promotes nasopharyngeal carcinoma cell cisplatin resistance via the miR-454/USP47 axis (Retraction of Vol 47, art no 54, 2021)

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

IF5.8

2024-02-061

OAAI

Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-12-238

OAAI

Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer

JOURNAL OF LEUKOCYTE BIOLOGY

IF3.1

2022-10-127

Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application

EUROPEAN JOURNAL OF PHARMACOLOGY

IF4.7

2021-09-0112

PRE

RETRACTED: Long non-coding RNA KCNQ1OT1 promotes nasopharyngeal carcinoma cell cisplatin resistance via the miR-454/USP47 axis (Retracted Article)

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

IF5.8

2021-02-1122

Pharmacological Treatment of Vascular Dementia: A Molecular Mechanism Perspective

AGING AND DISEASE

IF6.9

2021-01-0148

OAAI

Dynamic pricing in profit-driven task assignment: a domain-of-influence based approach

INTERNATIONAL JOURNAL OF MACHINE LEARNING AND CYBERNETICS

IF2.7

2020-10-147

PREAI

An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer

EXPERIMENTAL CELL RESEARCH

IF3.5

2020-05-018

PREAI

Characterization of the microRNA profile in early-stage cervical squamous cell carcinoma by next-generation sequencing

ONCOLOGY REPORTS

IF3.9

2017-01-167

OAAI

Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer

IMMUNOLOGIC RESEARCH

IF3.1

2015-11-2529

PREAI

A biosynthetic pathway for anandamide

anandamide的生物合成途径

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2006-09-05431

OAAI

Regulation of HSD17B1 and SRD5A1 in lymphocytes

MOLECULAR GENETICS AND METABOLISM

IF3.5

1999-11-0112

OAAI

Prominent sex steroid metabolism in human lymphocytes

MOLECULAR AND CELLULAR ENDOCRINOLOGY

IF3.6

1998-03-0148

OAAI

周智锋 (Zhifeng Zhou)

个人简介

教育背景

工作经历

荣誉奖项

研究方向